Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus MECLOFENAMATE SODIUM.
ANAPROX DS vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category C
Category C
NSAID
NSAID